Safeguard Scientifics Inc. has received $19.5 million in cash, and freed up another $12.3 million in cash due to one of its portfolio companies completing the second part of a private placement of convertible preferred stock.
TargetScan Touch Proven Effective in Duke Study
A study published in Technology in Cancer Research and Treatment shows that Envisioneering Medical’s TargetScan Touch system is more effective in detecting prostate cancer than traditional biopsy methods.
New Orleans to Promote City’s Bio-Boom
The New Orleans BioInnovation Center is embarking on a new campaign to lure bio industry workers back to the city.
Focal Drug Delivery Helps Deadly Brain Tumor, Study Shows
A method of delivering chemotherapy drugs into a deadly type of brain tumor extended the lives of patients in early clinical trials.
Clarient Launches New Breast Cancer Test
Clarient is launching a new breast cancer test that helps physicians assess the probability of a patient’s cancer returning.
Studies Back Gen-Probe’s Prostate Cancer Test
Eight studies presented this week at the American Urological Association Annual Meeting suggest that Gen-Probe’s investigational test for the prostate cancer gene PCA3 may address some of the major challenges faced by urologists when diagnosing the disease.
Provenge Extends Life of Prostate Cancer Patients, Study Finds
Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.
Pantec Reports Success In Transdermal Patch Trials
Some patients fear injections so much that they avoid getting proper medical treatment, sometimes with life-threatening results. Transdermal patches, which administer drugs through the skin, could make the bite of the needle a mere unpleasant memory.
